Drug Profile
RZ 358
Alternative Names: RZ-358; X 358; XOMA 247; XOMA 358; XPA.15.247Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator XOMA
- Developer Rezolute; XOMA
- Class Antihypoglycaemics; Monoclonal antibodies
- Mechanism of Action Insulin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Congenital hyperinsulinism
- Phase II Hypoglycaemia
Most Recent Events
- 06 Mar 2024 Rezolute plans a Phase III registrational trial for Hypoglycaemia
- 23 Jan 2024 Rezolute receives innovative passport under the innovative licensing and access pathway from the UK MHRA for RZ 358 in Congenital hyperinsulinism
- 11 Jan 2024 Phase-III clinical trials in Congenital-hyperinsulinism (In adolescents, In adults, In children, In infants) in France, Israel, Spain (IV) (NCT06208215)